Skip to content

Released Aug 14, 2025, after the close

10-Q filed Aug 14, 2025, 45 days after period end · 0001683168-25-006159

Q2 2025 · 10-Q
Revenue—
Net Income-$5.95MN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.30N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$5,968,877N/M
Operating Cash Flowderived-$4,173,761N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2025Q2 2024Q2 2023
Net Income-$5.95M-$6.57M-$5.52M
EPS Diluted-$0.30-$4.20-$3.88

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR